Do analysts rate ITRM or TNFA?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Iterum Therapeutics 1 Sell rating(s) 2 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.67 TNF Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Is ITRM or TNFA more profitable?

Iterum Therapeutics' return on equity of 0.00% beat TNF Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets Iterum Therapeutics N/A N/A -65.54% TNF Pharmaceuticals N/A -69.21% -33.98%

Do analysts prefer ERNA or ITRM?

Ernexa Therapeutics presently has a consensus price target of $30.00, suggesting a potential upside of 651.88%. Given Ernexa Therapeutics' stronger consensus rating and higher possible upside, equities analysts plainly believe Ernexa Therapeutics is more favorable than Iterum Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Ernexa Therapeutics 1 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 Iterum Therapeutics 1 Sell rating(s) 2 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.67

Is ERNA or ITRM more profitable?

Iterum Therapeutics' return on equity of 0.00% beat Ernexa Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Ernexa Therapeutics N/A -263.74% -151.16% Iterum Therapeutics N/A N/A -65.54%

Do analysts recommend ITRM or GELS?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Iterum Therapeutics 1 Sell rating(s) 2 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.67 Gelteq 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has preferable earnings and valuation, ITRM or GELS?

Gelteq has lower revenue, but higher earnings than Iterum Therapeutics. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Iterum Therapeutics $390K 4.10 -$24.77M -$0.75 N/A Gelteq $110K 72.34 -$4.30M N/A N/A

Is ITRM or GELS more profitable?

Company Net Margins Return on Equity Return on Assets Iterum Therapeutics N/A N/A -65.54% Gelteq N/A N/A N/A

Do analysts rate ITRM or PCSA?

Heatwurx has a consensus target price of $25.00, indicating a potential upside of 771.08%. Given Heatwurx's stronger consensus rating and higher probable upside, analysts clearly believe Heatwurx is more favorable than Iterum Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Iterum Therapeutics 1 Sell rating(s) 2 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.67 Heatwurx 1 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Is ITRM or PCSA more profitable?

Iterum Therapeutics' return on equity of 0.00% beat Heatwurx's return on equity. Company Net Margins Return on Equity Return on Assets Iterum Therapeutics N/A N/A -65.54% Heatwurx N/A -281.31% -200.80%

Do analysts recommend ITRM or PULM?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Iterum Therapeutics 1 Sell rating(s) 2 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.67 Pulmatrix 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Is ITRM or PULM more profitable?

Iterum Therapeutics' return on equity of 0.00% beat Pulmatrix's return on equity. Company Net Margins Return on Equity Return on Assets Iterum Therapeutics N/A N/A -65.54% Pulmatrix N/A -107.84% -91.58%

Iterum Therapeutics (ITRM) Competitors

$0.03 0.00 (0.00%)

As of 07/22/2026

Compare

ITRM vs. TNFA, ERNA, GELS, PCSA, and PULM

Should you buy Iterum Therapeutics stock or one of its competitors? MarketBeat compares Iterum Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Iterum Therapeutics include TNF Pharmaceuticals (TNFA), Ernexa Therapeutics (ERNA), Gelteq (GELS), Heatwurx (PCSA), and Pulmatrix (PULM). These companies are all part of the "pharmaceutical products" industry.

How does Iterum Therapeutics compare to TNF Pharmaceuticals?

Iterum Therapeutics (NASDAQ:ITRM) and TNF Pharmaceuticals (NASDAQ:TNFA) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their earnings, profitability, media sentiment, valuation, institutional ownership, analyst recommendations, risk and dividends.

Iterum Therapeutics has a beta of 2.96, suggesting that its stock price is 196% more volatile than the broader market. Comparatively, TNF Pharmaceuticals has a beta of 2.04, suggesting that its stock price is 104% more volatile than the broader market.

9.2% of Iterum Therapeutics shares are owned by institutional investors. Comparatively, 9.6% of TNF Pharmaceuticals shares are owned by institutional investors. 2.0% of Iterum Therapeutics shares are owned by company insiders. Comparatively, 0.5% of TNF Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Iterum Therapeutics' return on equity of 0.00% beat TNF Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Iterum Therapeutics	N/A	N/A	-65.54%
TNF Pharmaceuticals	N/A	-69.21%	-33.98%

In the previous week, Iterum Therapeutics' average media sentiment score of 0.00 equaled TNF Pharmaceuticals'average media sentiment score.

Company	Overall Sentiment
Iterum Therapeutics	Neutral
TNF Pharmaceuticals	Neutral

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Iterum Therapeutics	1 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.67
TNF Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

TNF Pharmaceuticals has lower revenue, but higher earnings than Iterum Therapeutics. Iterum Therapeutics is trading at a lower price-to-earnings ratio than TNF Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Iterum Therapeutics	$390K	4.10	-$24.77M	-$0.75	N/A
TNF Pharmaceuticals	N/A	N/A	-$23.36M	-$231.00	N/A

Summary

Iterum Therapeutics beats TNF Pharmaceuticals on 6 of the 10 factors compared between the two stocks.

How does Iterum Therapeutics compare to Ernexa Therapeutics?

Ernexa Therapeutics (NASDAQ:ERNA) and Iterum Therapeutics (NASDAQ:ITRM) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, risk, media sentiment, valuation, profitability, analyst recommendations, earnings and dividends.

In the previous week, Ernexa Therapeutics had 1 more articles in the media than Iterum Therapeutics. MarketBeat recorded 1 mentions for Ernexa Therapeutics and 0 mentions for Iterum Therapeutics. Ernexa Therapeutics' average media sentiment score of 0.00 equaled Iterum Therapeutics'average media sentiment score.

Company	Overall Sentiment
Ernexa Therapeutics	Neutral
Iterum Therapeutics	Neutral

Iterum Therapeutics' return on equity of 0.00% beat Ernexa Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Ernexa Therapeutics	N/A	-263.74%	-151.16%
Iterum Therapeutics	N/A	N/A	-65.54%

70.6% of Ernexa Therapeutics shares are owned by institutional investors. Comparatively, 9.2% of Iterum Therapeutics shares are owned by institutional investors. 0.5% of Ernexa Therapeutics shares are owned by company insiders. Comparatively, 2.0% of Iterum Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Ernexa Therapeutics presently has a consensus price target of $30.00, suggesting a potential upside of 651.88%. Given Ernexa Therapeutics' stronger consensus rating and higher possible upside, equities analysts plainly believe Ernexa Therapeutics is more favorable than Iterum Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Ernexa Therapeutics	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Iterum Therapeutics	1 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.67

Ernexa Therapeutics has higher revenue and earnings than Iterum Therapeutics. Ernexa Therapeutics is trading at a lower price-to-earnings ratio than Iterum Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Ernexa Therapeutics	$580K	8.05	-$14.08M	-$26.20	N/A
Iterum Therapeutics	$390K	4.10	-$24.77M	-$0.75	N/A

Ernexa Therapeutics has a beta of 2.5, suggesting that its share price is 150% more volatile than the broader market. Comparatively, Iterum Therapeutics has a beta of 2.96, suggesting that its share price is 196% more volatile than the broader market.

Summary

Ernexa Therapeutics beats Iterum Therapeutics on 8 of the 14 factors compared between the two stocks.

How does Iterum Therapeutics compare to Gelteq?

Iterum Therapeutics (NASDAQ:ITRM) and Gelteq (NASDAQ:GELS) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their risk, institutional ownership, media sentiment, analyst recommendations, earnings, profitability, dividends and valuation.

In the previous week, Iterum Therapeutics' average media sentiment score of 0.00 equaled Gelteq'saverage media sentiment score.

Company	Overall Sentiment
Iterum Therapeutics	Neutral
Gelteq	Neutral

Company	Net Margins	Return on Equity	Return on Assets
Iterum Therapeutics	N/A	N/A	-65.54%
Gelteq	N/A	N/A	N/A

Gelteq has lower revenue, but higher earnings than Iterum Therapeutics.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Iterum Therapeutics	$390K	4.10	-$24.77M	-$0.75	N/A
Gelteq	$110K	72.34	-$4.30M	N/A	N/A

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Iterum Therapeutics	1 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.67
Gelteq	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

9.2% of Iterum Therapeutics shares are owned by institutional investors. 2.0% of Iterum Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Iterum Therapeutics has a beta of 2.96, indicating that its share price is 196% more volatile than the broader market. Comparatively, Gelteq has a beta of -0.55, indicating that its share price is 155% less volatile than the broader market.

Summary

Iterum Therapeutics beats Gelteq on 5 of the 8 factors compared between the two stocks.

How does Iterum Therapeutics compare to Heatwurx?

Iterum Therapeutics (NASDAQ:ITRM) and Heatwurx (NASDAQ:PCSA) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their analyst recommendations, institutional ownership, dividends, risk, valuation, profitability, earnings and media sentiment.

Heatwurx has a consensus target price of $25.00, indicating a potential upside of 771.08%. Given Heatwurx's stronger consensus rating and higher probable upside, analysts clearly believe Heatwurx is more favorable than Iterum Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Iterum Therapeutics	1 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.67
Heatwurx	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

In the previous week, Iterum Therapeutics' average media sentiment score of 0.00 equaled Heatwurx'saverage media sentiment score.

Company	Overall Sentiment
Iterum Therapeutics	Neutral
Heatwurx	Neutral

Iterum Therapeutics has a beta of 2.96, suggesting that its stock price is 196% more volatile than the broader market. Comparatively, Heatwurx has a beta of 0.99, suggesting that its stock price is 1% less volatile than the broader market.

9.2% of Iterum Therapeutics shares are owned by institutional investors. Comparatively, 91.9% of Heatwurx shares are owned by institutional investors. 2.0% of Iterum Therapeutics shares are owned by company insiders. Comparatively, 3.5% of Heatwurx shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Iterum Therapeutics' return on equity of 0.00% beat Heatwurx's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Iterum Therapeutics	N/A	N/A	-65.54%
Heatwurx	N/A	-281.31%	-200.80%

Heatwurx has lower revenue, but higher earnings than Iterum Therapeutics. Heatwurx is trading at a lower price-to-earnings ratio than Iterum Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Iterum Therapeutics	$390K	4.10	-$24.77M	-$0.75	N/A
Heatwurx	N/A	N/A	-$13.56M	-$9.29	N/A

Summary

Iterum Therapeutics and Heatwurx tied by winning 6 of the 12 factors compared between the two stocks.

How does Iterum Therapeutics compare to Pulmatrix?

Iterum Therapeutics (NASDAQ:ITRM) and Pulmatrix (NASDAQ:PULM) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their analyst recommendations, institutional ownership, risk, media sentiment, profitability, valuation, dividends and earnings.

9.2% of Iterum Therapeutics shares are owned by institutional investors. Comparatively, 11.8% of Pulmatrix shares are owned by institutional investors. 2.0% of Iterum Therapeutics shares are owned by insiders. Comparatively, 0.6% of Pulmatrix shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Iterum Therapeutics' return on equity of 0.00% beat Pulmatrix's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Iterum Therapeutics	N/A	N/A	-65.54%
Pulmatrix	N/A	-107.84%	-91.58%

Pulmatrix has higher revenue and earnings than Iterum Therapeutics. Pulmatrix is trading at a lower price-to-earnings ratio than Iterum Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Iterum Therapeutics	$390K	4.10	-$24.77M	-$0.75	N/A
Pulmatrix	$7.81M	0.83	-$5.16M	-$1.23	N/A

Iterum Therapeutics has a beta of 2.96, suggesting that its stock price is 196% more volatile than the broader market. Comparatively, Pulmatrix has a beta of 1.9, suggesting that its stock price is 90% more volatile than the broader market.

In the previous week, Iterum Therapeutics' average media sentiment score of 0.00 equaled Pulmatrix'saverage media sentiment score.

Company	Overall Sentiment
Iterum Therapeutics	Neutral
Pulmatrix	Neutral

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Iterum Therapeutics	1 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.67
Pulmatrix	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Summary

Iterum Therapeutics beats Pulmatrix on 8 of the 11 factors compared between the two stocks.

Get Iterum Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ITRM and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ITRM vs. The Competition

Export

Metric	Iterum Therapeutics	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$1.60M	$3.06B	$6.81B	$12.60B
Dividend Yield	N/A	2.06%	2.68%	9.43%
P/E Ratio	-0.04	20.22	26.83	23.83
Price / Sales	4.10	340.49	519.01	91.18
Price / Cash	N/A	27.50	50.43	59.93
Price / Book	-0.20	4.20	10.02	6.10
Net Income	-$24.77M	$65.94M	$3.60B	$331.84M
7 Day Performance	N/A	-2.34%	-1.80%	-1.15%
1 Month Performance	N/A	-2.76%	-1.09%	-2.74%
1 Year Performance	N/A	11.15%	19.74%	14.97%

Iterum Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ITRM Iterum Therapeutics	N/A	$0.03 flat	N/A	N/A	$1.60M	$390K	N/A	10
TNFA TNF Pharmaceuticals	N/A	$3.45 +0.3%	N/A	-70.5%	$6.37M	N/A	N/A	6
ERNA Ernexa Therapeutics	3.0894 of 5 stars	$4.54 -16.4%	$30.00 +560.8%	-92.8%	$6.33M	$580K	N/A	10	Gap Down
GELS Gelteq	N/A	$0.61 +3.4%	N/A	-59.4%	$6.32M	$110K	N/A	N/A	High Trading Volume
PCSA Heatwurx	2.7606 of 5 stars	$2.24 +0.9%	$25.00 +1,016.1%	-52.3%	$6.14M	N/A	N/A	20

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ITRM) was last updated on 7/24/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Iterum Therapeutics (ITRM) Competitors

ITRM vs. TNFA, ERNA, GELS, PCSA, and PULM

How does Iterum Therapeutics compare to TNF Pharmaceuticals?

Summary

How does Iterum Therapeutics compare to Ernexa Therapeutics?

Summary

How does Iterum Therapeutics compare to Gelteq?

Summary

How does Iterum Therapeutics compare to Heatwurx?

Summary

How does Iterum Therapeutics compare to Pulmatrix?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ITRM vs. The Competition

Iterum Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Iterum Therapeutics (ITRM) Competitors

ITRM vs. TNFA, ERNA, GELS, PCSA, and PULM

How does Iterum Therapeutics compare to TNF Pharmaceuticals?

Which has more risk and volatility, ITRM or TNFA?

Do institutionals and insiders hold more shares of ITRM or TNFA?

Is ITRM or TNFA more profitable?

Does the media favor ITRM or TNFA?

Do analysts rate ITRM or TNFA?

Which has higher earnings and valuation, ITRM or TNFA?

Summary

How does Iterum Therapeutics compare to Ernexa Therapeutics?

Does the media refer more to ERNA or ITRM?

Is ERNA or ITRM more profitable?

Do insiders & institutionals have more ownership in ERNA or ITRM?

Do analysts prefer ERNA or ITRM?

Which has stronger earnings & valuation, ERNA or ITRM?

Which has more volatility & risk, ERNA or ITRM?

Summary

How does Iterum Therapeutics compare to Gelteq?

Does the media prefer ITRM or GELS?

Is ITRM or GELS more profitable?

Which has preferable earnings and valuation, ITRM or GELS?

Do analysts recommend ITRM or GELS?

Do institutionals & insiders have more ownership in ITRM or GELS?

Which has more volatility & risk, ITRM or GELS?

Summary

How does Iterum Therapeutics compare to Heatwurx?

Do analysts rate ITRM or PCSA?

Does the media prefer ITRM or PCSA?

Which has more volatility & risk, ITRM or PCSA?

Do institutionals and insiders have more ownership in ITRM or PCSA?

Is ITRM or PCSA more profitable?

Which has preferable earnings & valuation, ITRM or PCSA?

Summary

How does Iterum Therapeutics compare to Pulmatrix?

Do institutionals & insiders have more ownership in ITRM or PULM?

Is ITRM or PULM more profitable?

Which has stronger valuation & earnings, ITRM or PULM?

Which has more risk and volatility, ITRM or PULM?

Does the media prefer ITRM or PULM?

Do analysts recommend ITRM or PULM?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ITRM vs. The Competition

Iterum Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools